Patent 12122827 was granted and assigned to Asher Biotherapeutics on October, 2024 by the United States Patent and Trademark Office.
The present disclosure provides methods and compositions comprising IL-21 polypeptides, targeted cytokine construct that selectively activates target immune cells (e.g., CD8+ T cells) over other immune cell types. The cytokine of the present disclosure can further comprise mutations that alter its charge distribution to improve its half-life within the blood.